AstraZeneca

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

Oncology

Oncology 2023

Oncology 2023 features interviews, analysis, and commentary from pharmaphorum, industry leaders, and more

News

AstraZeneca pledges $400m to fight deforestation

AstraZeneca has said it will plant 200 million trees across six continents by 2030 in an effort to fight escalating rates of deforestation around the globe that is contrib

News

AZ may spin off its Chinese business, says report

AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t

News

AstraZeneca inks $2bn Treg cell therapy deal with Quell

UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which

News

FDA advisors back Beyfortus for RSV prevention

An FDA advisory committee has voted in favour of approving AstraZeneca and Sanofi’s one-shot antibody treatment to prevent respiratory syncytial virus (RSV) disease in inf

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

Oncology 2023

AstraZeneca pledges $400m to fight deforestation

AZ may spin off its Chinese business, says report

AstraZeneca inks $2bn Treg cell therapy deal with Quell

FDA advisors back Beyfortus for RSV prevention

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

AstraZeneca

Editor's Picks